mTOR pathway and mTOR inhibitors as agents for cancer therapy

Current Cancer Drug Targets

Volumn 8, Issue 8, 2008, Pages 647-665

  Baldo, Paolo ^a   Cecco, Sara ^a   Giacomin, Elisa ^a   Lazzarini, Renzo ^a   Ros, Barbara ^a   Marastoni, Stefano ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Cancer therapy; Clinical trial; Drug discovery; Investigational drugs; Molecular target; mTOR; Pathway; Rapamycin; Signal tranduction

Indexed keywords

ABI 009; AP 23765; BEZ 235; CARBOPLATIN; CORTICOSTEROID; CYCLOSPORIN; DEFOROLIMUS; DOXORUBICIN; EVEROLIMUS; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MK 8669; NAVELBINE; NSC 226080; NSC 606698; OSI 027; PACLITAXEL; PROMUS; R 440; RAPAMYCIN; RITUXIMAB; RO 317453; S6 KINASE; S6 KINASE 1; SALIRASIB; SB 1518; SF 1126; TAFA 93; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; XL 765; ZOTAROLIMUS;

APOPTOSIS; BONE MARROW SUPPRESSION; CANCER THERAPY; CELL GROWTH; CLINICAL TRIAL; DIARRHEA; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; GRAFT REJECTION; HUMAN; INFECTION; INTESTINE PERFORATION; KIDNEY CARCINOMA; MOUTH ULCER; MUCOSA INFLAMMATION; PNEUMONIA; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; NEOPLASMS; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 57449111076     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800908786733513     Document Type: Review

References (172)

1. Tsang, C. K.; Qi, H.; Liu, L. F.; Zheng, X. F. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov. Today 2007, 12, 112-124.
2. Bjornsti, M. A.; Houghton, P. J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 2004, 4, 335-348.
3. Chan, S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br. J. Cancer 2004, 91, 1420-1424.
4. Hay, N.; Sonenberg, N. Upstream and downstream of mTOR. Genes Dev. 2004, 18, 1926-1945.
5. Inoki, K.; Corradetti, M. N.; Guan, K. L. Dysregulation of the TSC-mTOR pathway in human disease. Nat. Genet. 2005, 7, 19-24.
6. Sabatini, D. M. mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 2006, 6, 729-734.
7. Seeliger, H.; Guba, M.; Kleespies, A.; Jauch, K. W.; Bruns, C. J. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev. 2007, 26, 611-621.
8. Rao, R. D.; Buckner, J. C.; Sarkaria, J. N. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. Curr. Cancer Drug Targets 2004, 4, 621-635.
9. Keith, C. T.; Schreiber, S. L. PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints. Science 1995, 270, 50-51.
10. Chen, J.; Zheng, X. F.; Brown, E. J.; Schreiber, S. L. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin- associated protein and characterization of a critical serine residue. Proc. Natl. Acad. Sci. USA 1995, 92, 4947-4951.
11. Brown, E. J.; Albers, M. W.; Shin, T. B.; Ichikawa, K.; Keith, C. T.; Lane, W. S.; Schreiber, S. L. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994, 369, 756-758.
12. Zheng, X. F.; Florentino, D.; Chen, J.; Crabtree, G. R.; Schreiber, S. L. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell 1995, 82, 121-130.
13. Heitman, J.; Movva, N. R.; Hall, M. N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991, 253, 905-909.
14. Abraham, R. T. Identification of TOR signaling complexes: more TORC for the cell growth engine. Cell 2002, 111, 9-12.
15. Crespo, J. L; Hall, M. N. Elucidating TOR signaling and rapamycin action: lessons from Saccharomyces cerevisiae. Microbiol. Mol. Biol. Rev. 2002, 66, 579-591.
16. Dames, S. A.; Mulet, J. M.; Rathgeb-Szabo, K.; Hall, M. N.; Grzesiek, S. The solution structure of the FATC domain of the protein kinase target of rapamycin suggests a role for redox-dependent structural and cellular stability. J. Biol. Chem. 2005, 280, 20558-20564.
17. Tsang, C. K.; Zheng , X. F. TOR-in(g) the nucleus. Cell Cycle 2007, 6, 25-29.
18. Desai, B. N.; Myers, B. R.; Schreiber, S. L. FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction. Proc. Natl. Acad. Sci. USA 2002, 99, 4319-4324.
19. Drenan, R. M.; Liu, X.; Bertram, P. G.; Zheng, X. F. FKBP12-rapamycin- associated protein or mammalian target of rapamycin (FRAP/mTOR) localization in the endoplasmic reticulum and the Golgi apparatus. J. Biol. Chem. 2004, 279, 772-778.
20. Liu, X.; Zheng, X. F. Endoplasmic reticulum and Golgi localization sequences for mammalian target of rapamycin. Mol. Biol. Cell. 2007, 18, 1073-1082.
21. Kim, J. E.; Chen, J. Cytoplasmic-nuclear shuttling of FKBP12-rapamycin-associated protein is involved in rapamycin-sensitive signaling and translation initiation. Proc. Natl. Acad. Sci. USA 2000, 97, 14340-14345.
22. Sarbassov, D. D.; Ali, S. M.; Kim, D. H.; Guertin, D. A.; Latek, R. R.; Erdjument-Bromage, H.; Tempst, P.; Sabatini, D. M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 2004, 14, 1296-1302.
23. Wullschleger, S.; Loewith, R.; Oppliger, W.; Hall, M. N. Molecular organization of target of rapamycin complex 2. J. Biol. Chem. 2005, 280, 30697-30704.
24. Thedieck, K.; Polak, P.; Kim, M. L.; Molle, K. D.; Cohen, A.; Jenö, P.; Arrieumerlou, C.; Hall, M. N. PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. PLoS ONE 2007, 2, 1217.
25. Yang, Q.; Inoki, K.; Ikenoue, T.; Guan, K. L. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev. 2006, 20, 2820-2832.
26. Pearce, L. R.; Huang, X.; Boudeau, J.; Pawłowski, R.; Wullschleger, S.; Deak, M.; Ibrahim, A. F.; Gourlay, R.; Magnuson, M. A.; Alessi, D. R. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem. J. 2007, 405, 513-522.
27. Hara, K.; Maruki, Y.; Long, X.; Yoshino, K.; Oshiro, N.; Hidayat, S.; Tokunaga, C.; Avruch, J.; Yonezawa, K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002, 110, 177-189.
28. Fonseca, B. D.; Smith, E. M.; Lee, V. H. Y.; MacKintosh, C.; Proud, C. G. PRAS40 Is a Target for Mammalian Target of Rapamycin Complex 1 and Is Required for Signaling Downstream of This Complex. J. Biol. Chem. 2007, 282, 24514-24524.
29. Nojima, H.; Tokunaga, C.; Eguchi, S.; Oshiro, N.; Hidayat, S.; Yoshino, K.; Hara, K.; Tanaka, N.; Avruch, J.; Yonezawa, K. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J. Biol. Chem. 2003, 278, 15461-15464.
30. Sarbassov, D. D.; Ali, S. M.; Sengupta, S.; Sheen, J. H.; Hsu, P. P.; Bagley, A. F.; Markhard, A. L.; Sabatini, D. M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell. 2006, 22, 159-168.
31. Gangloff, Y. G.; Mueller, M.; Dann, S. G.; Svoboda, P.; Sticker, M.; Spetz, J. F.; Um, S. H.; Brown, E. J.; Cereghini, S.; Thomas, G.; Kozma, S. C. Disruption of the mouse mTOR gene leads to early post-implantation lethality and prohibits embryonic stem cell development. Mol. Cell. Biol. 2004, 24, 9508-9516.
32. Barbet, N. C.; Schneider, U.; Helliwell, S. B.; Stansfield, I.; Tuite, M. F.; Hall, M. N. TOR controls translation initiation and early G1 progression in yeast. Mol. Biol. Cell. 1996, 7, 25-42.
33. Tzatsos, A.; Kandror, K. V. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol. Cell. Biol. 2006 26, 63-76.
34. Reiling, J. H.; Sabatini, D. M. Stress and mTORture signaling. Oncogene 2006, 25, 6373-6383.
35. Engelman, J. A.; Luo, J.; Cantley, L. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. 2006, 7, 606-619.
36. Sarbassov, D. D.; Ali, S. M.; Sabatini, D. M. Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 2005, 17, 596-603.
37. Jiang, B. -H.; Liu, L. -Z. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist. Updat. 2008, 11, 63-76.
38. Mocanu, M. M.; Yellon, D. M. PTEN, the Achilles' heel of myocardial ischemia/reperfusion injury? Br. J. Pharmacol. 2007, 150, 833-838.
39. Garami, A.; Zwartkruis, F. J.; Nobukuni, T.; Joaquin, M.; Roccio, M.; Stocker, H.; Kozma, S. C.; Hafen, E.; Bos, J. L.; Thomas, G. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell. 2003, 11, 1457-1466.
40. Tee, A. R.; Manning, B. D.; Roux, P. P.; Cantley, L. C.; Blenis, J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 2003, 13, 1259-1268.
41. Bai, X.; Ma, D.; Liu, A.; Shen, X.; Wang, Q. J.; Liu, Y.; Jiang, Y. Rheb Activates mTOR by Antagonizing Its Endogenous Inhibitor, FKBP38. Science 2007, 318, 977-980.
42. Gingras, A. C.; Kennedy, S. G.; O'Leary, M. A.; Sonenberg, N.; Hay, N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev. 1998, 12, 502-513.
43. Jozwiak, J.; Jozwiak, S. Giant cells: contradiction to two-hit model of tuber formation? Cell. Mol. Neurobiol. 2007, 27, 251-261.
44. Oldham, S.; Montagne J.; Radimerski, T.; Thomas, G.; Hafen, E. Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. Genes Dev. 2000, 14, 2689-2694.
45. Radimerski, T.; Montagne, J.; Hemmings-Mieszczak, M.; Thomas, G. Lethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6K signaling. Genes Dev. 2002, 16, 2627-2632.
46. Pyronnet, S.; Imataka, H.; Gingras, A. -C.; Fukunaga1, R.; Hunter, T.; Sonenberg, H. Human eukaryotic translation initiation factor 4G (eIF4G) recruits Mnk1 to phosphorylate eIF4E. EMBO J. 1999, 18, 270-279.
47. Hershey, P. E. C.; McWhirter, S. M.; Gross, J. D.; Wagner, G.; Alber, T.; Sachs, A. B. The Cap-binding Protein eIF4E Promotes Folding of a Functional Domain of Yeast Translation Initiation Factor eIF4G1. J. Biol. Chem. 1999, 274, 21297-21304.
48. Sonenberg, N.; Gingras, A. -C. The mRNA 5′ cap-binding protein elF4E and control of cell growth. Curr. Opin. Cell Biol. 1998, 10, 268-275
49. Gingras, A. -C.; Gygi, S. P.; Raught, B.; Polakiewicz, R. D.; Abraham, R. T.; Hoekstra, M. F.; Aebersold, R.; Sonenberg, N. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. 1999, 13, 1422-1437.
50. Ma, X. M.; Yoon, S.; Richardson, C. J.; Jülich, K.; Blenis, J. SKAR links pre-mRNA splicing to mTOR/S6K1-mediated enhanced translation efficiency of spliced mRNAs. Cell 2008, 133, 303-313.
51. Faivre, S.; Kroemer, G.; Raymond, E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug. Discov. 2006, 8, 671-88.
52. Haruta, T.; Uno, T.; Kawahara, J.; Takano, A.; Egawa, K.; Sharma, P. M.; Olefsky, J. M.; Kobayashi, M.; A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol. Endocrinol. 2000, 6, 783-794.
53. Guertin, D. A.; Sabatini, D. M. Defining the role of mTOR in cancer. Cancer Cell. 2007, 12, 9-22.
54. Manning, B. D. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J. Cell Biol. 2004, 167, 399-403.
55. Harrington, L. S.; Findlay, G. M.; Lamb, R. F. Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem. Sci. 2005, 30, 35-42.
56. Garcia, J. A.; Danielpour, D. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol. Cancer Ther. 2008, 7, 1347-1354.
57. Shintani, T.; Klionsky, D. J. Autophagy in health and disease: a double-edged sword. Science 2004, 306, 990-995.
58. Wendel, H. G.; De Stanchina, E.; Fridman, J. S.; Malina, A.; Ray, S.; Kogan, S.; Cordon-Cardo, C.: Pelletier, J.; Lowe, S. W. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004, 428, 332-337.
59. Kanzawa, T.; Germano, I. M.; Komata, T.; Ito, H.; Kondo, Y.; Kondo, S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 2004, 11, 448-457.
60. Zeng, X.; Kinsella, T. J. Mammalian Target of Rapamycin and S6 Kinase 1 Positively Regulate 6-thioguanine-Induced Autophagy. Cancer Res. 2008, 68, 2384-2390.
61. Wan, X.; Harkavy, B.; Shen, N.; Grohar, P.; Helman, L. J. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26, 1932-1940.
62. Petricoin, E. F.; Espina, V.; Araujo, R. P.; Midura, B.; Yeung, C.; Wan, X.; Eichler, G. S.; Johann, D. J.; Qualman, S.; Tsokos, M.; Krishnan, K.; Helman, L. J.; Liotta, L. A.; Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res. 2007, 67, 3431-3440.
63. Mamane, Y.; Petroulakis, E.; Rong, L.; Yoshida, K,; Ler, L. W.; Sonenberg, N. eIF4E--from translation to transformation. Oncogene 2004, 23, 3172-3179.
64. De Benedetti, A.; Graff, J. R. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004, 23, 3189-3199.
65. Noh, W. C.; Kim, Y. H.; Kim, M. S.; Koh, J. S.; Kim, H. -A.; Moon, N. M.; Paik, N. -S. Activation of the mTOR signalling pathway in breast cancer and its correlation with the clinicopathologic variables. Breast Cancer Res. Treat. 2008, 110, 477-483.
66. Zhou, S.; Wang, G. -P.; Liu, C.; Zhou, M. Initiation Factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer BMC Cancer 2006, 6, 231 (available at: http://www.biomedcentral.com/1471- 2407/6/231).
67. Castelvi, J.; Garcia, A.; Rojo, F.; Ruiz-Marcellan, C.; Gil, A.; BAselga, J.; Cajal, S. R. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with serviva in ovarian cancer. Cancer 2006, 107, 1081-1811.
68. Fingar, D. C.; Salama, S.; Tsou, C.; Harlow, E.; Blenis, J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002, 16, 1472-1487.
69. Oldham, S.; Hafen, E. Insulin/IGF and target of rapamycin signaling: a TOR de force in growth control. Trends Cell Biol. 2003, 13, 79-85.
70. Braun-Dullaeus, R. C.; Mann, M. J.; Seay, U.; Zhang, L.; Von Der Leyen, H. E.; Morris, R. E.; Dzau, V. J. Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. Arterioscler. Thromb. Vasc. Biol. 2001, 21, 1152-1158.
71. Douros, J.; Suffness, M. New natural products under development at the National Cancer Institute. Recent Results Cancer Res. 1981, 76, 153-175.
72. Sawyers, C. L. Will mTOR inhibitors make it as cancer drugs? Cancer Cell 2003, 4, 343-348.
73. Lazaris-Karatzas, A.; Montine K. S.; Sonenberg, N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. Nature 1990, 345, 544-547.
74. Montagne, J.; Stewart, M. J.; Stocker, H.; Hafen, E.; Kozma, S. C.; Thomas, G. Drosophila S6 kinase: a regulator of cell size. Science 1999, 285, 2126-2129.
75. Edinger, A. L.; Thompson, C. B. Death by design: apoptosis, necrosis and autophagy. Curr. Opin. Cell. Biol. 2004, 16, 663-669.
76. Edinger, A. L.; Thompson, C. B. An activated mTOR mutant supports growth factor-independent, nutrient-dependent cell survival. Oncogene 2004, 23, 5654-5663.
77. Fingar, D. C.; Blenis, J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004, 23, 3151-3171.
78. Dilling, M. B.; Germain, G. S.; Dudkin, L.; Jayaraman, A. L.; Zhang, X.; Harwood, F. C.; Houghton, P. J. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J. Biol. Chem. 2002, 277, 13907-13917.
79. Nathan, C. A.; Carter, P.; Liu, L.; Li, B. D.; Abreo, F.; Tudor, A.; Zimmer, S. G.; De Benedetti, A. Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas. Oncogene 1997, 15, 1087-1094.
80. Avdulov, S.; Li, S.; Michalek, V.; Burrichter, D.; Peterson, M.; Perlman, D. M.; Manivel, J. C.; Sonenberg, N.; Yee, D.; Bitterman, P. B.; Polunovsky, V. A. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 2004, 5 553-563.
81. Berkel, H. J.; Turbat-Herrera, E. A.; Shi, R.; De Benedetti, A. Expression of the translation initiation factor eIF4E in the polypcancer sequence in the colon. Cancer Epidemiol. Biomarkers Prev. 2001, 10, 663-666.
82. Bussink, J.; Van der Kogel, A. J.; Kaanders, J. H. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol. 2008, 9, 288-296.
83. Neshat, M. S.; Mellinghoff, I. K.; Tran, C.; Stiles, B.; Thomas, G.; Petersen, R.; Frost, P.; Gibbons, J. J.; Wu, H.; Sawyers, C. L. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA 2001, 98, 10314-10319.
84. Kaper, F.; Dornhoefer, N.; Giaccia, A. J. Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. Cancer Res. 2006, 66, 1561-1569.
85. Black, D.; Bogomolniy, F.; Robson, M. E.; Offit, K.; Barakat, R. R.; Boyd, J. Evaluation of germline PTEN mutations in endometrial cancer patients. Gynecol. Oncol. 2005, 96, 21-24.
86. Yilmaz, O. H.; Valdez, R.; Theisen, B. K.; Guo, W.; Ferguson, D. O.; Wu, H.; Morrison, S. J. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006, 441, 475-482.
87. McMenamin, M. E.; Soung, P.; Perera, S.; Kaplan, I.; Loda, M.; Sellers, W. R. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 1999, 59, 4291-4296.
88. Kwiatkowski, D. J.; Manning, B. D. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum. Mol. Genet. 2005, 14, 251-258.
89. Jozwiak, J.; Jozwiak, S.; Wlodarski, P. Possible mechanisms of disease development in tuberous sclerosis. Lancet Oncol. 2008, 9, 73-79.
90. Astrinidis, A.; Henske, E. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene 2005, 24, 7475-7481.
91. Abraham, R. T. PI 3-kinase related kinases: 'big' players in stress-induced signaling pathways. DNA Repair (Amst.) 2004, 3, 883-887.
92. Brugarolas, J. B.; Vazquez, F.; Reddy, A.; Sellers, W. R.; Kaelin, W. G. Jr. TSC2 regulates VEGF through mTOR-dependent and - independent pathways. Cancer Cell 2003, 4, 147-158.
93. Marimpietri, D.; Brignole, C.; Nico, B.; Pastorino, F.; Pezzolo, A.; Piccardi, F.; Cilli. M,; Di Paolo, D.; Pagnan, G.; Longo, L.; Perri, P.; Ribatti, D.; Ponzoni, M. Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis. Clin. Cancer Res. 2007, 13, 3977-3988.
94. Land, S. C.; Tee, A. R. Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via a mTOR signaling motif. J. Biol. Chem. 2007, 282, 20534-20543.
95. Guba, M.; Koehl, G. E.; Neppl E.; Doenecke, A.; Steinbauer, M.; Schlitt, H. J.; Jauch, K. W.; Geissler, E. K. Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl. Int. 2005, 18, 89-94.
96. Campistol, J. M.; Gutierrez-Dalmau, A.; Torregrosa, J. V. Conversion to sirolimus: a successful treatment for post-transplantation Kaposi's sarcoma. Transplantation 2004, 77, 760-762.
97. Stallone, G.; Schena, A.; Infante, B.; Di Paolo, S.; Loverre, A.; Maggio, G.; Ranieri, E.; Gesualdo, L.; Schena, F. P.; Grandaliano, G. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N. Engl. J. Med. 2005, 352, 1317-1323.
98. Li, W.; Petrimpol, M.; Molle, K. D.; Hall, M. N.; Battegay, E. J.; Humar, R. Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2. Circ. Res. 2007, 100, 79-87.
99. Woo, S. Y.; Kim, D. H.; Jun, C. B.; Kim, Y. M.; Haar, E. V.; Lee, S. I.; Hegg, J. W.; Bandhakavi, S.; Griffin, T. J.; Kim, D. H. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling. J. Biol. Chem. 2007, 282, 25604-25612.
100. Lee, D. F.; Hung, M. C. All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle 2007, 6, 3011-3014.
101. Rowinsky, E. K. Targeting the molecular target of rapamycin (mTOR). Curr. Opin. Oncol. 2004, 16, 564-575.
102. Vignot, S.; Faivre, S.; Aguirre, D.; Raymond, E. m-TOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol. 2005, 16, 525-537.
103. Informations accessed throught R&D Insight (Research and Development Insight) at http://bi.adisinsight.com/Login/Login.aspx
104. Garlich, J. R.; De, P.; Dey, N.; Su, J. D.; Peng, X.; Miller, A.; Murali, R.; Lu, Y.; Mills, G. B.; Kundra, V.; Shu, H. K.; Peng, Q.; Durden, D. L. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 2008, 68, 206-215.
105. Sehgal, S. N.; Baker, H.; Vezina, C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. Antibiot. 1975, 28, 727-732.
106. Easton, J. B.; Houghton, P. J. mTOR and cancer therapy. Oncogene 2006, 25, 6436-6446.
107. Schmelzle, T.; Hall, M. N. TOR, a central controller of cell growth. Cell 2000, 103, 253-262.
108. Namba, R.; Young, L. J.; Abbey, C. K.; Kim, L.; Damonte, P.; Borowsky, A. D.; Qi, J.; Tepper, C. G.; MacLeod, C. L.; Cardiff, R. D.; Gregg, J. P. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. Clin. Can. Res. 2006, 12, 2613-2621.
109. Wimmer, C. D.; Rentsch, M; Crispin, A.; Illner, W. D.; Arbogast, H.; Graeb, C.; Jauch, K. W.; Guba, M. The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int. 2007, 71, 1271-1278.
110. Huang, S.; Shu, L.; Easton, J.; Harwood, F. C.; Germain, G. S.; Ichijo, H.; Houghton, P. J. Inhibition of mammalian target rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity. J. Biol. Chem. 2004, 179, 36490-36496.
111. Huang, S.; Shu, L.; Dilling, M. B.; Easton, J.; Harwood, F. C.; Ichijo, H.; Houghton, P. J. Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21 (Cip1). Mol. Cell 2003, 11, 1491-1501.
112. Hosoi, H.; Dilling, M. B.; Shikata, T.; Liu, L. N.; Shu, L.; Ashmun, R. A.; Germain, G. S.; Abraham, R. T.; Houghton, P. J. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-indipendent apoptosis in human rhabdomyosarcoma cells. Cancer Res. 1999, 59, 886-894.
113. Krishnamachary, B.; Berg-Dixon, S.; Kelly, B.; Agani, F.; Feldser, D.; Ferreira, G.; Iyer, N.; LaRusch, J.; Pak, B.; Taghavi, P.; Semenza, G. L. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res. 2003, 63, 1138-1143.
114. Lang, S. A.; Gaumann, A.; Koehl, G. E.; Seidel, U.; Bataille, F.; Klein, D.; Ellis, L. M.; Bolder, U.; Hofstaedter, F.; Schlitt, H. J.; Geissler, E. K.; Stoeltzing, O. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int. J. Cancer 2007, 120, 1803-1810.
115. Mita, M. M.; Mita, A. C.; Chu, Q. S.; Rowinsky, E. K.; Fetterly, G. J.; Goldston, M.; Patnaik, A.; Mathews, L.; Ricart, A. D.; Mays, T.; Knowles, H.; Rivera, V. M.; Kreisberg, J.; Bedrosian, C. L.; Tolcher, A. W. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J. Clin. Oncol. 2008, 28, 361-367.
116. Rizzieri, D. A.; Feldman, E.; Di Persio, J. F.; Gabrail, N.; Stock, W.; Strair, R.; Rivera, V. M.; Albitar, M.; Bedrosian, C. L.; Giles, F. J. Phase 2 Clinical Trial of Deforolimus (AP23573,MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies. Clin. Cancer Res. 2008, 14, 2756-2762.
117. Vivano, I.; Sawyers, C. L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2, 489-501.
118. Therasse, P.; Arbuck, S. G.; Eisenhauer, E. A.; Wanders, J.; Kaplan, R. S.; Rubinstein, L.; Verweij, J.; Van Glabbeke, M.; Van Oosterom, A. T.; Christian, M. C.; Gwyther, S. G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000, 92, 205-216.
119. Chawla, S. P.; Sankhala, K. K.; Chua, V.; Menendez, L. R.; Eilber, F. C. A phase II study of AP23573 (an mTOR inhibitor) in patients with advanced sarcomas. J. Clin. Oncol. 2005, 23(Suppl.), 9068.
120. Marimpietri, D.; Nico, B.; Vacca, A.; Mangieri, D.; Catarsi, P.; Ponzoni, M.; Ribatti, D. Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin. Oncogene 2005, 24, 6785-6795.
121. Ribatti, D.; Nico, B.; Mangieri, D.; Longo, V.; Sansonno, D.; Vacca, A.; Dammacco, F. In vivo inhibition of human hepatocellular carcinoma related angiogenesis by vinblastine and rapamycin. Histol. Histolpathol. 2007, 22, 285-289.
122. Haritunians, T.; Mori, A.; O'Kelly, J.; Luong, Q. T.; Giles, F. J.; Koeffler, H. P. Antiproliferative activity of RAD-001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 2007, 21, 333-339.
123. Wanner, K.; Hipp, S.; Oelsner, M.; Ringshausen, I.; Bogner, C.; Peschel, C.; Decker, T. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br. J. Haematol. 2006, 134, 475-484.
124. Boulay, A.; Rudloff, J.; Ye, J.; Zumstein-Mecker, S.; O'Reilly, T.; Evans, D. B.; Chen, S.; Lane, H. A. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin. Can. Res. 2005, 11, 5319-5328.
125. Treeck, O.; Wackwitz, B.; Haus, U.; Ortmann, O. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol. Oncol. 2006, 102, 292-299.
126. Geoerger, B.; Kerr, K.; Tang, C. B.; Fung, K. M.; Powell, B.; Sutton, L. N.; Phillips, P. C.; Janss, A. J. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res. 2001, 61, 1527-1532.
127. Ito, D.; Fujimoto, K.; Mori, T.; Kami, K.; Koizumi, M.; Toyoda, E.; Kawaguchi, Y.; Doi, R. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int. J. Cancer 2006, 118, 2337-2343.
128. Thallinger, C.; Werzowa, J.; Poeppl, W.; Kovar, F. M.; Pratscher, B.; Valent, P.; Quehenberger, P.; Joukhadar, C. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice. J. Invest. Dermatol. 2007, 127, 2411-2417.
129. Thallinger, C.; Poeppl, W.; Pratscher, B.; Mayerhofer, M.; Valent, P.; Tappeiner, G.; Joukhadar, C. CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model. Pharmacology 2007, 79, 207-213.
130. Albert, J. M.; Kim, K. W.; Cao, C.; Lu, B. Targeting the Akt/mammalian target of rapamycin pathway for radiosenitization of breast cancer. Mol. Cancer Ther. 2006, 5, 1183-1189.
131. Moretti, L.; Yang, E. S.; Kim, K. W.; Lu, B. Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy. Drug Resist. Updat. 2007, 10, 135-143.
132. Shinohara, E. T.; Cao, C.; Niermann, K.; Mu, Y.; Zeng, F.; Hallahan, D. E.; Lu, B. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 2005, 24, 5414-5422.
133. Punt, C. J.; Boni, J.; Bruntsch, U.; Peters, M.; Thielert, C. Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann. Oncol. 2003, 14, 931-937.
134. Sarkaria, J. N.; Schwingler, P.; Schild, S. E.; Grogan, P. T.; Mladek, A. C.; Mandrekar, S. J.; Tan, A. D.; Kobayashi, T.; Marks, R. S.; Kita, H.; Miller, R. C.; Limper, A. H.; Leof, E. B. Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer. J. Thorac. Oncol. 2007, 2, 751-757.
135. Pacey, S.; Steven, N.; Brock, C. Results of a phase I clinical trial investigating a combination of the oral mTOR-inhibitor everolimus and gemcitabine in patients with advanced cancers. J. Clin. Oncol. 2004, 22, 3120.
136. Morgillo, F.; Lee, H. Y. Resistance to epidermal growth factor receptor-targeted therapy. Drug Resist. Updat. 2005, 8, 298-310.
137. Reardon, D. A.; Quinn, J. A.; Vredenburgh, J. J.; Gururangan, S.; Friedman, A. H.; Desjardins, A.; Sathornsumetee, S.; Herndon, J. E. 2nd; Dowell, J. M.; McLendon, R. E.; Provenzale, J. M.; Sampson, J. H.; Smith, R. P.; Swaisland, A. J.; Ochs, J. S.; Lyons, P.; Tourt-Uhlig, S.; Bigner, D. D.; Friedman, H. S.; Rich, J. N. Phase I trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin. Cancer Res. 2006, 12, 860-868.
138. Doherty, L.; Gigas, D. C.; Kesari, S.; Drappatz, J.; Kim, R.; Zimmerman, J.; Ostrowsky, L.; Wen, P. Y. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 2006, 67, 156-158.
139. Milton, D. T.; Riely, G. J.; Azzoli, C. G.; Gomez, J. E.; Heelan, R. T.; Kris, M. G.; Krug, L. M.; Pao, W.; Pizzo, B.; Rizvi, N. A.; Miller, V. A. Phase I trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer 2007, 110, 599-605.
140. Riely, G. J.; Kris, M. G.; Zhao, B.; Akhurst, T.; Milton, D. T.; Moore, E.; Tyson, L.; Pao, W.; Rizvi, N. A.; Schwartz, L. H.; Miller, V. A. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin. Cancer Res. 2007, 13, 5150-5155.
141. Sleijfer, S.; Wiemer, E.; Seynaeve, C.; Verweij, J. Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment. Oncologist 2007, 12, 719-726.
142. Radulovic, S.; Bjelogrlic, S. K. Sunitinib, sorafenib and mTOR inhibitors in renal cancer. J. BUON 2007, 12, S151-S162.
143. Liu, L.; Cao, Y.; Chen, C.; Zhang, X.; McNabola, A.; Wilkie, D.; Wilhelm, S.; Lynch, M.; Carter, C.; Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006, 66, 11851-11858.
144. Beeram, M.; Tan, Q. T.; Tekmal, R. R.; Russell, D.; Middleton, A.; DeGraffenried, L. A. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann. Oncol. 2007, 18, 1323-1328.
145. Landis-Piwowar, K. R.; Milacic, V.; Chen, V. The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist. Updates 2006, 9, 263-273.
146. Smolewski, P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 2006, 17, 487-494.
147. Thomas, G. V. mTOR and cancer: reason for dancing at the crossroads? Curr. Opin. Genet. Dev. 2006, 16, 78-84.
148. Kurmasheva, R. T.; Huang, S.; Houghton, P. J. Predicted mechanism of resistance to mTOR inhibitors. Br. J. Cancer 2006, 95, 955-960.
149. Kim, H. L.; Seligson, D.; Liu, X.; et al. Using tumor markers to predict survival of patients with metastatic renal cell carcinoma. J. Urology 2005, 173, 1496-1501.
150. Baak, J. P.; Van Diermen, B.; Steinbakk, A.; Janssen, E.; Skaland, I.; Mutter, G. L.; Fiane, B.; Løvslett, K. Lack of PTEN expression in endometrial intraepithelial neoplasia is correlated with cancer pregression. Hum. Pathology 2005, 36, 555-556.
151. Chiang, G. G.; Abraham, R. T. Targeting the mTOR signaling network in cancer. Trends Mol. Med. 2007, 13, 433-442.
152. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3, 721-732.
153. Thomas, G. V.; Tran, C.; Mellinghoff, I. K. Hypoxia inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. 2006, 12, 122-127.
154. Zhou, X.; Tan, M.; Stone Hawthorne, V.; Klos, K. S.; Lan, K. H.; Yang, Y.; Yang, W.; Smith, T. L.; Shi, D.; Yu, D. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancer. Clin. Cancer Res. 2004, 10, 6779-6788.
155. Pantuck, A. J.; Selingson, D. B.; Klatte, T.; Yu, H.; Leppert, J. T.; Moore, L.; O'Toole, T.; Gibbons, J.; Belldegrun, A. S.; Figlin, R. A. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007, 109, 2257-2267.
156. Legrier, M. E.; Yang, C. P.; Yan, H. G.; Lopez-Barcons, L.; Keller, S. M.; Pérez-Soler, R.; Horwitz, S. B.; McDaid, H. M. Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res. 2007, 67, 11300-11308
157. Li, X.; Lin, G.; Wu, B.; Zhou, X.; Zhou, K. Overexpression of PTEN induces cell growth arrest and apoptosis in human breast cancer ZR-75-1 cells. Acta Biochim. Biophys. Sin. 2007, 39, 745-750.
158. Fan, Q. W.; Cheng, C. K.; Nicolaides, T. P.; Hackett, C. S.; Knight, Z. A.; Shokat, K. M.; Weiss, W. A. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res. 2007, 67, 7960-7965.
159. Nathan, C. O.; Amirghahari, N.; Rong, X.; Giordano, T.; Sibley, D.; Nordberg, M.; Glass, J.; Agarwal, A.; Caldito, G. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res. 2007, 67, 2160-2168.
160. Zhang, H.; Liu, G.; Dziubinski, M.; Yang, Z.; Ethier, S. P.; Wu, G. Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells. Breast Cancer Res. Treat. 2007, 12, [Epub ahead of print].
161. Furuya, F.; Lu, C.; Willingham, M. C.; Cheng, S. Y. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. Carcinogenesis 2007, 28, 2451-2458.
162. Kato, S.; Iida, S.; Higuchi, T.; Ishikawa, T.; Takagi, Y.; Yasuno, M.; Enomoto, M.; Uetake, H.; Sugihara, K. PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int. J. Cancer 2007, 121, 1771-1778.
163. Vogt, P. K.; Kang, S.; Elsliger, M. A.; Gymnopoulos, M. Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem. Sci. 2007, 32, 342-349.
164. Costa, L. J.; Gemmill, R. M.; Drabkin, H. A. Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells. Urology 2007, 69, 596-602.
165. Wendel, H. G.; Silva, R. L.; Malina, A.; Mills, J. R.; Zhu, H.; Ueda, T.; Watanabe-Fukunaga, R.; Teruya-Feldstein, J.; Pelletier, J.; Lowe, S. W. Dissecting eIF4E action in tumorigenesis. Genes Dev. 2007, 21, 3232-3237.
166. Siegele, B.; Cefalu, C.; Holm, N.; Sun, G.; Tubbs, J.; Meschonat, C.; Odaka, Y.; DeBenedetti, A.; Ghali, G. E.; Chu, Q.; Mathis, J. M.; Li, B. D. eIF4E-targeted suicide gene therapy in a minimal residual mouse model for metastatic soft-tissue head and neck squamous cell carcinoma improves disease-free survival. J. Surg. Res. 2008, 148, 83-89.
167. Zhang, H.; Bajraszewski, N.; Wu, E.; Wang, H.; Moseman, A. P.; Dabora, S. L.; Griffin, J. D.; Kwiatkowski, D. J. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J. Clin. Invest. 2007, 117, 730-738.
168. Meikle, L.; Talos, D. M.; Onda, H.; Pollizzi, K.; Rotenberg, A.; Sahin, M.; Jensen, F. E. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J. Neurosci. 2007, 27, 5546-5558.
169. Holz, M. K.; Blenis, J. Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J. Biol. Chem. 2005, 280, 26089-26093.
170. Savinska, L. O.; Lyzogubov, V. V.; Usenko, V. S.; Ovcharenko, G. V.; Gorbenko, O. N.; Rodnin, M. V.; Vudmaska, M. I.; Pogribniy, P. V.; Kyyamova, R. G.; Panasyuk, G. G.; Nemazanyy, I. O.; Malets, M. S.; Palchevskyy, S. S.; Gout, I. T.; Filonenko, V. V. Immunohistochemical analysis of S6K1 and S6K2 expression in human breast tumors. Eksp. Onkol. 2004, 26, 24-30.
171. Toschi, A.; Edelstein, J.; Rockwell, P.; Ohh, M.; Foster, D. A. HIF-alpha expression in VHL-deficient renal cancer cells is dependent on phospholipase D. Oncogene 2008 27, 2746-2753.
172. Vleugel, M. M.; Bos, R.; Buerger, H.; Van der Groep, P.; Saramäki, O. R.; Visakorpi, T.; Van der Wall, E.; Van Diest, P. J. No amplifications of hypoxia-inducible factor-1alpha gene in invasive breast cancer: a tissue microarray study. Cell Oncol. 2004, 26, 347-351.